TITLE

SHIRE SIGNS DEAL WITH SAMARITAN TO LAUNCH REPAGAL FOR FABRY

PUB. DATE
July 2007
SOURCE
Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the exclusive marketing and distribution deal signed by Samaritan Pharmaceuticals with Shire Human Genetic Therapies AB for the launching and selling of Replagal (agalsidase alfa), a drug approved in Europe for Fabry disease, in Greece and Cyprus. A total of 41 countries has approved the drug for commercial use. Information on the mechanism and the side effects of the drug is outlined.
ACCESSION #
25547356

 

Related Articles

  • Treatment for Hunter Syndrome Approved.  // FDA Consumer;Sep/Oct2006, Vol. 40 Issue 5, p4 

    The article reports that the U.S. Food and Drug Administration has approved Elaprase, the first product for the treatment of Hunter syndrome or Mucopolysaccharidosis in July 2006. Elaprase was designated as an orphan product by the FDA, a designation granted to products that treat rare diseases...

  • NEW DRUGS.  // Drug Topics;9/4/2006, Vol. 150 Issue 17, p71 

    The article evaluates new drugs including MoviPrep from Salix Pharmaceuticals, Elaprase, a treatment for Hunter Syndrome (mucopolysaccharidosis II) from Shire Human Genetic Therapies and Xolegel, treatment for seborrheic dermatitis from Barrier Therapeutics.

  • Phillips: demystifying Regulation 2.0. Lewis, Tanya // Medical Marketing & Media;Dec2008, Vol. 43 Issue 12, p36 

    The article discusses how Cynthia Phillips, director of regulatory advertising, promotion and global labeling for Shire Human Genetics Therapies Inc. (HGT) is campaigning for Web 2.0. In 2008, Phillips has given Web 2.0 presentations at three conferences not as a representative of Shire but as a...

  • Applications Update.  // PharmaWatch: Biotechnology;Apr2010, Vol. 9 Issue 4, p14 

    The article offers updates on drug applications. The drug candidate for weight management, lorcaserin, from Biogen Arena Pharmaceuticals Inc. has been accepted for filling by the U.S. Food and Drug Administration (FDA). Shire Human Genetic Therapies Inc.'s Replagal, an enzyme replacement therapy...

  • Shire Looks to Social Media To Launch HAE Drug Firazyr. Serebrov, Mari // BioWorld Today;8/26/2011, Vol. 22 Issue 166, p1 

    This article reports on the use of social media by Shire Human Genetic Therapies (HGT) to launch its Firazyr, a self-administered injectable treatment for acute attacks of hereditary angioedema (HAE) in adults. Shire announced the launch of the drug after it was approved by the U.S. Food and...

  • Decisions Update.  // PharmaWatch: Biotechnology;Apr2010, Vol. 9 Issue 4, p15 

    The article offers updates on drug application decisions. The U.S. Food and Drug Administration (FDA) gave marketing approval to VPRIV from Shire Human Genetic Therapies Inc. for the treatment of type 1 Gaucher disease. Rituxan from Genentech Inc. and Biogen Idec Inc. received approval from the...

  • Staying Home. McCurry, John W. // Site Selection;May/Jun2009, Vol. 54 Issue 3, p399 

    The article reports on the expansion of businesses in Massachusetts. It notes that the new campus of Shire Human Genetic Therapies Inc. (HGT) located at the old Raytheon Inc. headquarters in Lexington. According to Pat Sacco, vice president of Shire HGT, the Raytheon site offers the best...

  • GREEK MINISTRY APPROVES PRICE INCREASE FOR AMPHOCIL.  // Worldwide Biotech;Apr2007, Vol. 19 Issue 4, p8 

    The article reports that Samaritan Pharmaceuticals Inc. received approval from the Greek Ministry of Development to increase the price of the drug AMPHOCIL The firm was able to obtain a price increase reaching the level of 94 percent, which is said to be the second highest price increase granted...

  • DRUM ROLL PLEASE. Edwards, John // Las Vegas Business Press (10712186);7/30/2007, Vol. 24 Issue 31, p7 

    The article reports on the confirmation made by Southern Nevada pharmaceutical company Samaritan Pharmaceuticals on the ability of its innovative drug Caprospinol to decrease beta amyloid plaque in the brain. The drug also can complete recovery of memory back to baseline as shown in a Morris...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics